Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.45 -1.25%
Revenue Growth %: -4.4%
Financial Fact:
Discontinued operations--net of tax: 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.4%
Financial Fact:
Discontinued operations--net of tax: 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q4 EPS of $0.63, $0.15 better than the analyst estimate of $0.48. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.28 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $2.80-$3.00, versus the consensus of $2.93. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $63 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
